Omada Health Reviews Liraglutide
Supported like any other GLP-1, with the coaching emphasis shifted toward daily-injection adherence rather than the escalation-window nausea that dominates the weekly agents.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “Companion support” means here
The vendor does not prescribe this molecule. It supports members whose prescription was written elsewhere.
The pairing
How Omada Health handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Companion support
- Gating
- None from Omada.
- Prescribes directly
- No
- Step therapy
- No
- Prior authorization
- No
- Titration protocol
- Not applicable — prescription stays with the member's own clinician or your PBM pathway
- Off-ramp
- Structured 12-week taper support with strength programming to defend lean mass
- Care team
- Registered dietitians, CDCES-certified coaches, Exercise physiologists
Ask Omada Health this
How do your persistence rates on daily liraglutide compare with the weekly agents in the same population?
Watch out
Confirm exactly which fees are at risk and how engagement is defined — the definition moves the guarantee more than the percentage does.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Teladoc Health Navigation & orchestration | Adjunct | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Calibrate Full-service clinical | Adjunct | 7.2 | $65–$110 |
| Transcarent Navigation & orchestration | Orchestrated | 7.1 | $12–$32 |
| WeightWatchers Clinic Consumer-brand clinical | Adjunct | 6.9 | $30–$68 |
Same vendor
Omada Health across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
Omada writes no prescription. It wraps a semaglutide script issued by your PBM pathway or the member's own clinician, concentrating on the escalation window where discontinuation clusters and on protein and resistance programming to defend lean mass.
Same companion posture as semaglutide, with coaching cadence tuned to tirzepatide's longer escalation ladder — more months of support before a member reaches maintenance.